Anteris Technologies Announces Postponement of Stockholder Meeting
In an important communication to stakeholders, Anteris Technologies Global Corp. recently declared that it has decided to postpone its upcoming Special Meeting of Stockholders. This meeting was originally intended for a live discussion to take place on September 4, 2025. Anteris, known for its innovative work in the medical device sector, has opted to reschedule this event to September 11, 2025.
Reasons for the Postponement
The decision to delay the Special Meeting is aimed at encouraging wider participation amongst stockholders. The Board of Directors is actively promoting the opportunity for stockholders to engage and cast their votes on the proposals outlined in the Proxy Statement, filed with the SEC before the initial meeting date.
Voting Information
For investors who have already cast their votes, it is essential to understand that those votes will remain valid and do not require any corrective action. This process can help ensure that those who have taken action are not inconvenienced by the rescheduling.
For Those Who Have Not Voted
Stockholders who have not participated in the voting process will have the opportunity to do so via the instructions provided in the Proxy Statement. It is important to note that votes submitted online or through telephone channels should be finalized by September 10, 2025, while mail-in votes must also be received by the same deadline to ensure they are counted in the postponed meeting.
Important Details about Participation
For those holding CHESS Depositary Interests (CDIs), it is essential to complete the CDI Voting Instruction Form in a timely manner. These instructions should be sent to Computershare, the designated agent, ensuring that they are submitted by the stipulated deadlines for inclusion in the vote tally.
Proxy Statement Insights
The recent notice emphasizes that stockholders should read the definitive Proxy Statement thoroughly, especially as it contains critical details about the voting proposals and related background. To support informed decision-making, both old and new information in this notice will supersede any contradictory details found in the earlier Proxy Statement.
About Anteris Technologies
Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is dedicated to revolutionizing the cardiovascular health landscape. They specialize in creating advanced medical devices aimed at enhancing heart functionality. This commitment is evident in their flagship product, the DurAVR Transcatheter Heart Valve, which addresses significant cardiovascular challenges such as aortic stenosis. This technology has proven its efficacy in clinical applications worldwide, demonstrating Anteris' pivotal role in addressing heart disease.
Innovative Heart Solutions
The DurAVR device represents a leap forward in heart valve technology, focusing on maximizing patient outcomes. Its innovative design mimics the healthy functioning of natural heart valves, which is integral in restoring normal blood flow and function for patients suffering from heart diseases.
Frequently Asked Questions
What led to the postponement of the Special Meeting?
The postponement was made to allow stockholders more time to vote, promoting higher engagement and participation in the decision-making process.
How can stockholders vote in the upcoming Special Meeting?
Stockholders can vote by following the instructions provided in the Proxy Statement. Voting can be executed via mail, telephone, or online methods prior to the deadlines given.
What should I do if I’ve already voted?
If you have already voted, there is no need for further action, as your vote will remain valid for the rescheduled Special Meeting.
Where can I read the Proxy Statement?
Stockholders can obtain the Proxy Statement from the SEC’s website or through the investor section of Anteris' own website for complete details.
What is Anteris Technologies known for?
Anteris Technologies is renowned for its cutting-edge work in the field of structural heart disease, particularly with its innovative DurAVR heart valve technology, aiding patients with severe aortic stenosis.
